Table 5.

Survival analysis of prognostic factors for overall survival and disease-free survival in locally advanced 52 PTCs (pT4)^*.

Overall survival
Characteristics	Univariate analysis			Multivariate analysis
	HR	95%CI	p	HR	95%CI	p
Gender Male vs. Female	0.41	(0.08-2.28)	0.3100
Age (years)	1.15	(1.03-1.28)	0.0150	1.13	(0.96-1.33)	0.1384
Tumor Size (cm)	0.85	(0.48-1.48)	0.5560
N1b vs. N0/N1a	2.3	(0.27-19.7)	0.4480
M1 vs. M0	36.5	(4.24-313.91)	0.0010	29.22	(2.57-331.79)	0.0065
TIGIT Positive vs. Negative	8.81	(0.91-85.62)	0.0610
LAG3 Positive vs. Negative	1.27	(0.15-10.88)	0.8290
VISTA Moderate & Strong vs. Weak & Negative	13.79	(1.4-135.91)	0.0250	42.23	(1.76-1013.87)	0.0210
B7H3 Moderate & Strong vs. Weak & Negative	3.53	(0.63-19.93)	0.1530
CTLA4 Positive vs. Negative	1.39	(0.16-11.91)	0.7650
TIM3 Positive vs. Negative	1.96	(0.36-10.7)	0.4380
Disease Free Survival
Characteristics	Univariate analysis			Multivariate analysis
	HR	95%CI	p	HR	95%CI	p
Gender Male vs. Female	0.98	(0.24-3.96)	0.9760
Age (years)	1.12	(1.02-1.22)	0.0140	1.04	(0.94-1.15)	0.4567
Tumor Size (cm)	0.88	(0.56-1.4)	0.6020
N1b vs. N0/N1a	1.34	(0.27-6.65)	0.7230
M1 vs. M0	24.78	(4.98-123.44)	<0.001	32.85	(2.6-415.45)	0.0070
TIGIT Positive vs. Negative	6.57	(0.73-59.2)	0.0930
LAG3 Positive vs. Negative	0.92	(0.11-7.47)	0.9340
VISTA Positive vs. Negative	5.64	(1.1-28.99)	0.0380	12.94	(1.45-115.73)	0.0220
B7H3 Moderate & Strong vs. Weak & Negative	6.43	(1.24-33.39)	0.0270	0.55	(0.06-5.08)	0.6004
CTLA4 Positive vs. Negative	0.93	(0.11-7.59)	0.9480
TIM3 Positive vs. Negative	1.24	(0.25-6.14)	0.7960

*Six patients were lost to follow-up.

The bold values indicates that the p values are less than 0.05, which is considered statistically significant.